ALX Oncology Overview
- Founded
-
2015
- Status
-
Public
- Employees
-
55
- Stock Symbol
-
ALXO
- Investments
-
1
- Share Price
-
$9.30
- (As of Tuesday Closing)
ALX Oncology General Information
Description
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Contact Information
Website
www.alxoncology.com
Formerly Known As
Alexo Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 866 Malcolm Road
- Suite 100
- Burlingame, CA 94010
- United States
ALX Oncology Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.30 | $9.28 | $5.82 - $20.40 | $378M | 40.8M | 174K | -$2.98 |
ALX Oncology Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 77,658 | 485,889 | 2,944,944 | |
| Revenue | 0 | 0 | 1,182 | 4,796 |
| EBITDA | (123,349) | (83,420) | (44,486) | (18,759) |
| Net Income | (121,211) | (83,463) | (45,740) | (19,243) |
| Total Assets | 317,689 | 380,183 | 436,054 | 10,676 |
| Total Debt | 6,600 | 742 | 0 | 5,421 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
ALX Oncology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ALX Oncology Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by develo
Drug Discovery
Burlingame, CA
55
As of 2022
00000
00000000
00000
000000
oris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehend
0000000000000
Vancouver, Canada
000
As of 0000
00000
0000
0000-00-00
000000000000
00000
a aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nis
0000 000000000
Wadenswil, Switzerland
00
As of 0000
00000
0000
0000-00-00
00000000000
00000
Add Comparison
ALX Oncology Competitors (2)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Zymeworks | Formerly VC-backed | Vancouver, Canada | 000 | 00000 | 000000000000 | |
| 00000 0000 0000000 | Venture Capital-Backed | Wadenswil, Switzerland | 00 | 00000 | 00000000000 | 00000 |
ALX Oncology Patents
ALX Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220363779-A1 | Combination therapies for treating cancer | Pending | 13-May-2021 | 000000000 | |
| US-20220196651-A1 | Multimers for reducing the interference of drugs that bind cd47 in serological assays | Pending | 06-Dec-2020 | 000000000000 | |
| US-20220401516-A1 | Combination therapies comprising a hypomethylation agent for treating cancer | Pending | 01-Jun-2020 | 00000000000 | |
| CA-3178157-A1 | Combination therapies comprising a hypomethylation agent for treating cancer | Pending | 01-Jun-2020 | ||
| AU-2021283083-A1 | Combination therapies comprising a hypomethylation agent for treating cancer | Pending | 01-Jun-2020 | A61K38/1703 |
ALX Oncology Executive Team (12)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Jaume Pons Ph.D | Chief Executive Officer & Founder | ||
| Peter Garcia | Chief Financial Officer, Finance | ||
| Shelly Pinto | Chief Accounting Officer, Accounting & Vice President | ||
| Jeanne Jew | Chief Business Officer | ||
| Hank Stern | Vice President, Chemistry, Manufacturing & Controls |
ALX Oncology Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Caroline Gaynor | Lightstone Ventures | Board Member | 000 0000 |
| Corey Goodman Ph.D | ALX Oncology | Chairman & Board Member | 000 0000 |
| Itziar Canamasas | ALX Oncology | Board Member | 000 0000 |
| Jack Nielsen | Vivo Capital | Board Member | 000 0000 |
| Jason Lettmann | Lightstone Ventures | Board Member | 000 0000 |
ALX Oncology Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
ALX Oncology Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 | 04-Oct-2021 | 0000000000 | 00.00 | Biotechnology |
ALX Oncology ESG
Risk Overview
Risk Rating
Updated December, 06, 2022
30.92 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,613
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 1,004
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 462
Rank
00.00
Percentile
